Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — LSX Nordic Congress 2024
15 slides from Cantargia Ab's conference presentation, Oct 8, 2024
Slide 1: Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases
Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases Corporate Presentation October 2024 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Cantargia – Investment highlights
Cantargia – Investment highlights NOVEL IL1RAP ANTIBODIES, POTENTIAL TO TREAT CANCER & INFLAMMATORY DISEASE • IL1RAP elevated in most solid and liquid tumors • IL1RAP signaling drives several autoimmune and inflammatory diseases NADUNOLIMAB: CLEAR ACTIVITY SIGNALS IN CANCER THERAPY WITH UPCOMING CAT
Slide 4: Current pipeline
Current pipeline Asset Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 PDAC**, Nadunolimab TNBC*, NSCLC** Hidradenitis Suppurativa CAN10 Systemic Sclerosis New opportunities within CANxx IL1RAP platform PDAC – pancreatic cancer; TNBC – triple-negative breast cancer; NSCLC – non-small cell l
Slide 5: CAN10 – Opportunity in autoimmune/inflammatory disease
CAN10 – OPPORTUNITY IN AUTOIMMUNE/INFLAMMATORY DISEASE
Slide 6: CAN10 developed to block IL-1 family with precision
CAN10 developed to block IL-1 family with precision • CAN10 prevents signaling from IL1/, IL-33 and IL36// • CAN10 binds IL1RAP with pM affinity and prevents IL1RAP interaction with the IL-1, IL-33 and IL-36 receptors • CAN10 has shown robust efficacy in preclinical models of several diseases •
Slide 7: CAN10 first-in-human study - SAD part
CAN10 first-in-human study - SAD part Design • Blinded, placebo-controlled study • Nine dose groups from 1 to 400 mg CAN10 incl 2 patients on placebo in each group Results • No safety signals • Strong PD effects (IL-36 at Cmax and day 8) • Receptor occupancy documented (at Cmax) IL-36 stimulation (D
Slide 8: CAN10 for treatment of Hidradenitis Suppurativa (HS)
CAN10 for treatment of Hidradenitis Suppurativa (HS) IL-36R-blockade (spesolimab) elicited positive results on overall disease severity1 • Efficacy shown in Phase 2 randomized controlled study (NCT04762277) by changes in iHS4, HASI-R, and HiSCR50, with a particular effect on draining tunnels (dTs) •
Slide 9: Nadunolimab (CAN04) overview
NADUNOLIMAB (CAN04) OVERVIEW
Slide 10: IL1RAP overexpressed in most solid tumors
IL1RAP overexpressed in most solid tumors IL1RAP EXPRESSION IN SOLID TUMOR TYPES SEVERAL TUMOR-PROMOTING CELLS EXPRESSING IL1RAP IN THE TUMOR MICROENVIRONMENT 100% IL1RAP-expressing tumors 75% 50% 25% 0% C ic as t al r ea l C er CL at e ct iL ve g SC d N S r e B r r e ha N lad nc lo op H B Pa Co Es
Slide 11: PDAC – IL1RAP linked to poor prognosis
PDAC – IL1RAP linked to poor prognosis IL1RAP IN PDAC KRAS MUTATIONS IN PDAC IL1RAP IL1RAP KRAS mutations Tumor cells 12 ✱✱ 12 ✱✱✱✱ 8.8% 10 10 Other Log2(TPM) 8 8 15.0% 36.6% Fibroblasts WT G12D 6 6 1.2% G12C 4 4 25.8% 12.7% 2 2 G12V G12R Macrophages 0 0 WT G12D G12R G12V Stage 1-3 4 → IL1RAP levels
Slide 12: Pancreatic cancer – Efficacy and IL1RAP level
Pancreatic cancer – Efficacy and IL1RAP level OS by IL1RAP subgroup IL1RAP High IL1RAP Low 50% Best change in tumor size iCPD 0% iUPD iSD iPR -50% -100% Efficacy analysis for IL1RAP High (n=29) vs IL1RAP Low (n=20) PDAC patients (1st line, combination with Gem/Abraxane): → Significantly prolonged OS
Slide 13: Non-small cell lung cancer: Strongest effects in patients no longer responding to PD1-inhibitors
Non-small cell lung cancer: Strongest effects in patients no longer responding to PD1-inhibitors MODIFICATIONS IN TUMOR MICROENVIRONMENT FAVORABLE FOR NADUNOLIMAB THERAPY AND MAY BE LINKED TO STRONG EFFICACY OBSERVED
Slide 14: Keytruda combination: promising signs of clinical activity
Keytruda combination Promising signs of clinical activity with remarkable benefit in a subset of patients COMBINATION WITH PEMBROLIZUMAB SHOWS LONG SURVIVAL CORRELATING WITH TUMOR MICROENVIRONMENT CHARACTERISTICS
Slide 15: Upcoming milestones
Upcoming milestones Nadunolimab Additional PDAC TNBC AML/MDS CAN10 milestones • Phase IIb trial in 150- •Randomized Phase II •Start phase I/II mid • Phase I data updates • New clinical data 200 patients top-line data in H1 2024 (DOD sponsored during 2024 (including presented from 2025 with MDA) safe